Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This clinical trial tests whether contrast-enhanced ultrasound can predict the response of
bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced
ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also
possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping
of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may
also help doctors see if ultrasound-triggered microbubble popping can improve bile duct
cancer response to radiotherapy. Another purpose of this trial is to test if the pressure
inside the tumor estimated through ultrasound can be used to predict the tumor response to
radiotherapy.